On November 3, 2022 Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, reported acceptance of a poster presentation at 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition being held December 10-13 in New Orleans, Louisiana (Press release, Aptevo Therapeutics, NOV 3, 2022, View Source [SID1234623131]). Details of the presentation, which will be presented live, are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: "Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome"
Date/Time: Sunday, December 11, 2022, 6:00 PM-8:00 PM
Presenter: Justin M. Watts, MD, Associate Professor of Medicine Section Chief, Leukemia, Pap Corps Endowed Professor in Leukemia, Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine